A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL).
Michael Wang
Consultant or Advisory Role - Janssen Research & Development
Honoraria - Janssen Research & Development
Research Funding - Janssen Research & Development; Pharmacyclics
Leo I. Gordon
No relevant relationships to disclose
Simon Rule
Consultant or Advisory Role - NAPP Pharmaceuticals; Pharmacyclics; Roche
Andre Goy
Consultant or Advisory Role - Johnson & Johnson; Pharmacyclics
Research Funding - Johnson & Johnson; Pharmacyclics
Olivier Hermine
Honoraria - Johnson & Johnson
Aleksandra Rizo
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Sen Hong Zhuang
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Martin H. Dreyling
Consultant or Advisory Role - Janssen Research & Development; Roche
Honoraria - Janssen Research & Development; Mundipharma; Roche
Research Funding - Janssen Research & Development; Mundipharma; Roche